These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10202226)

  • 1. Emergency department management of pneumonia.
    Talan DA; Moran GJ
    Can Respir J; 1999; 6 Suppl A():10A-4A. PubMed ID: 10202226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approaches to treatment of community-acquired pneumonia in the emergency department and the appropriate role of fluoroquinolones.
    Moran G
    J Emerg Med; 2006 May; 30(4):377-87. PubMed ID: 16740445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis and management of community-acquired pneumonia in adults.
    Watkins RR; Lemonovich TL
    Am Fam Physician; 2011 Jun; 83(11):1299-306. PubMed ID: 21661712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pneumonia in clinical practice: diagnosis and therapy].
    Zimmerli W
    Praxis (Bern 1994); 1994 Dec; 83(49):1374-7. PubMed ID: 7801011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates.
    Pérez-Trallero E; Marimon JM; Iglesias L; Larruskain J
    Emerg Infect Dis; 2003 Sep; 9(9):1159-62. PubMed ID: 14519256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing community-acquired pneumonia. Factors to consider in outpatient care.
    Farber MO
    Postgrad Med; 1999 Apr; 105(4):106-14. PubMed ID: 10223090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance of Streptococcus pneumoniae to fluoroquinolones--United States, 1995-1999.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2001 Sep; 50(37):800-4. PubMed ID: 11785571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for drug-resistant Streptococcus pneumoniae and antibiotic prescribing practices in outpatient community-acquired pneumonia.
    Jenkins TC; Sakai J; Knepper BC; Swartwood CJ; Haukoos JS; Long JA; Price CS; Burman WJ
    Acad Emerg Med; 2012 Jun; 19(6):703-6. PubMed ID: 22632455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empirical therapy of community-acquired pneumonia: macrolides are not ideal choices.
    Bartlett JG
    Semin Respir Infect; 1997 Dec; 12(4):329-33. PubMed ID: 9436960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of atypical pathogens of community-acquired pneumonia.
    Plouffe JF
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S35-9. PubMed ID: 10984326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The role of quinolones in the treatment of community acquired pneumonia].
    Garau J
    Med Clin (Barc); 1998 Feb; 110 Suppl 1():31-5. PubMed ID: 9717158
    [No Abstract]   [Full Text] [Related]  

  • 12. The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia.
    Weiss K; Tillotson GS
    Chest; 2005 Aug; 128(2):940-6. PubMed ID: 16100190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Urinary pneumococcal or Legionella antigen detection tests and low-spectrum antibiotic therapy for community-acquired pneumonia].
    Roger PM; Risso K; Hyvernat H; Landraud L; Vassallo M; Dellamonica J; de Salvador F; Cua E; Bernardin G
    Med Mal Infect; 2010 Jun; 40(6):347-51. PubMed ID: 20172672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia.
    Lynch III JP; Martinez FJ
    Clin Infect Dis; 2002 Mar; 34 Suppl 1():S27-46. PubMed ID: 11810608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting.
    Segreti J; House HR; Siegel RE
    Am J Med; 2005 Jul; 118 Suppl 7A():21S-28S. PubMed ID: 15993674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microbiological and pharmacodynamic considerations in the treatment of infection due to antimicrobial-resistant Streptococcus pneumoniae.
    Appelbaum PC
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S29-34. PubMed ID: 10984325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial resistance in Streptococcus pneumoniae: implications for patients with community-acquired pneumonia.
    Chenoweth CE; Saint S; Martinez F; Lynch JP; Fendrick AM
    Mayo Clin Proc; 2000 Nov; 75(11):1161-8. PubMed ID: 11075746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The hospitalist perspective on treatment of community-acquired bacterial pneumonia.
    Amin AN; Cerceo EA; Deitelzweig SB; Pile JC; Rosenberg DJ; Sherman BM
    Postgrad Med; 2014 Mar; 126(2):18-29. PubMed ID: 24685965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Community-acquired pneumonia].
    Blanquer J; Sanz F
    Arch Bronconeumol; 2010 Oct; 46 Suppl 7():26-30. PubMed ID: 21316547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.